Search Result

Results for "

α2-Adrenoceptor Agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adrenergic Receptor (63) Akt (6) Antibiotic (1) Apoptosis (13) Autophagy (7) Bacterial (1) Dopamine Receptor (10) Drug Metabolite (1) Histone Methyltransferase (5) Imidazoline Receptor (15) Isotope-Labeled Compounds (11) LDLR (8) Parasite (3) Reference Standards (18) Vasopressin Receptor (1) Wnt (6) β-catenin (6)
By Research Areas:	Cancer (29) Cardiovascular Disease (30) Endocrinology (26) Infection (4) Metabolic Disease (1) Neurological Disease (41)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17034A

Dexmedetomidine hydrochloride Maximum Cited Publications 26 Publications Verification (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride	Adrenergic Receptor	Infection Cancer
Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of *α2-adrenoceptor, with a K_i* of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-12719

Dexmedetomidine Maximum Cited Publications 26 Publications Verification (+)-Medetomidine; (S)-Medetomidine	Adrenergic Receptor	Neurological Disease Cancer
Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of *α2-adrenoceptor, with a K_i* of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .

HY-B0409A

Clonidine hydrochloride 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Clonidine hydrochloride is an agonist of *α2-adrenoceptor* and potent antihypertensive agent.

HY-B0194A

Tizanidine hydrochloride	Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central *α₂-adrenoceptor* agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI) .

HY-B0194

Tizanidine	Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine, a skeletal muscle relaxant, is an orally effective central *α₂-adrenoceptor* agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI) .

HY-100490

Rilmenidine	Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy	Cardiovascular Disease Cancer
Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an *alpha 2-adrenoceptor* agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na ⁺/H ⁺ antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .

HY-17034

Medetomidine	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine is an orally active *α2-adrenoceptor* agonist (K_i: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-12724

Guanabenz 2 Publications Verification	Adrenergic Receptor Parasite	Cardiovascular Disease Cancer
Guanabenz is an orally active *α-2-adrenoceptor* agonist. Guanabenz has antihypertensive effect and antiparasitic activity. Guanabenz interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz also is used for the research of high blood pressure .

HY-109075A

Tasipimidine sulfate	Adrenergic Receptor	Neurological Disease
Tasipimidine sulfate is an orally active and selective *α_2A-adrenoceptor* agonist with a pEC₅₀ of 7.57 for human α_2A-adrenoceptors and an EC₅₀ of 5.7 nM for rat *α₂-adrenoceptor*. Tasipimidine sulfate can be utilized in research related to situational anxiety and fear .

HY-100490B

Rilmenidine phosphate	Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy	Cardiovascular Disease Cancer
Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine phosphate is an *alpha 2-adrenoceptor* agonist. Rilmenidine phosphate induces autophagy. Rilmenidine phosphate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na ⁺/H ⁺ antiport. Rilmenidine phosphate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .

HY-17034B

Medetomidine hydrochloride MPV785	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine hydrochloride is an orally active *α2-adrenoceptor* agonist (K_i: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-12724A

Guanabenz hydrochloride	Parasite Adrenergic Receptor	Cardiovascular Disease Cancer
Guanabenz hydrochloride is an orally active *α-2-adrenoceptor* agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure .

HY-B0354A

Urapidil hydrochloride	5-HT Receptor Adrenergic Receptor	Cardiovascular Disease Infection Neurological Disease Metabolic Disease
Urapidil hydrochloride is an orally active and blood-brain barrier permeability *α1-adrenoceptor* antagonist and 5-HT_1A receptor agonist with a pIC₅₀ of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect .

HY-12707

Piribedil 1 Publications Verification	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a *α2-adrenoceptors* antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-B0374

Moxonidine BDF5895	Imidazoline Receptor Adrenergic Receptor LDLR	Cardiovascular Disease Neurological Disease
Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and *α₂ adrenoceptors*, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-100490A

Rilmenidine hemifumarate	Imidazoline Receptor Adrenergic Receptor Apoptosis Autophagy	Cardiovascular Disease Cancer
Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an *alpha 2-adrenoceptor* agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na ⁺/H ⁺ antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .

HY-B0374A

Moxonidine hydrochloride BDF5895 hydrochloride	Imidazoline Receptor Adrenergic Receptor LDLR	Cardiovascular Disease Neurological Disease
Moxonidine (BDF5895) hydrochloride is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine hydrochloride activates imidazoline I₁ receptors and *α₂ adrenoceptors*, affecting oxidized low-density lipoprotein uptake. Moxonidine hydrochloride reduces atherosclerotic lesions and lowers blood pressure. Moxonidine hydrochloride can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-17034BS1

Medetomidine-13C,d3 hydrochloride MPV785-¹³C,d₃	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Medetomidine-13C,d3 (hydrochloride) is a deuterated labeled Medetomidine (hydrochloride) . Medetomidine hydrochloride is an orally active *α2-adrenoceptor* agonist (K_i: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-103203

ST91	Adrenergic Receptor	Neurological Disease
ST91 is a α₂-adrenoceptor (α₂AR) agonist. ST91 activates both α_2AAR and non-α_2AAR subtypes to produce spinal antinociception .

HY-17034AR

Dexmedetomidine hydrochloride (Standard) (+)-Medetomidine hydrochloride (Standard); (S)-Medetomidine hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine (hydrochloride) (Standard) is the analytical standard of Dexmedetomidine (hydrochloride). This product is intended for research and analytical applications. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of *α2-adrenoceptor, with a K_i* of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-12719R

Dexmedetomidine (Standard) (+)-Medetomidine (Standard); (S)-Medetomidine (Standard)	Reference Standards Adrenergic Receptor	Neurological Disease Cancer
Dexmedetomidine (Standard) is the analytical standard of Dexmedetomidine. This product is intended for research and analytical applications. Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of *α2-adrenoceptor, with a K_i* of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .

HY-106865

Mivazerol	Dopamine Receptor Adrenergic Receptor	Cardiovascular Disease
Mivazerol is a selective *α2-adrenoceptor* agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research _.

HY-A0008

Talipexole dihydrochloride B-HT 920 dihydrochloride	Adrenergic Receptor Dopamine Receptor 5-HT Receptor	Neurological Disease Endocrinology
Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.

HY-B0194S

Tizanidine-d4	Isotope-Labeled Compounds Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine-d₄ is the deuterium labeled Tizanidine (HY-B0194). Tizanidine, a skeletal muscle relaxant, is an orally effective central *α₂-adrenoceptor* agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-103212A

Azepexole hydrochloride B-HT 933 hydrochloride; Oxazoloazepin hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Azepexole hydrochloride (B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride) is a selective agonist for *α 2-adrenoceptor, with pK_i* of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively. Azepexole dihydrochloride causes concentration-dependent inhibition of peristaltic contractions with IC₅₀ of 78.72 nM. Azepexole hydrochloride exhibits antitussive and analgesic efficacy .

HY-B0409S

Clonidine-d4	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Clonidine-d₄ is the deuterium labeled Clonidine. Clonidine hydrochloride is an agonist of α2-adrenoceptor and potent antihypertensive agent .

HY-B0354AR

Urapidil hydrochloride (Standard)	Reference Standards 5-HT Receptor Adrenergic Receptor	Cardiovascular Disease Endocrinology
Urapidil (hydrochloride) (Standard) is the analytical standard of Urapidil (hydrochloride). This product is intended for research and analytical applications. Urapidil hydrochloride is an orally active *α1-adrenoceptor* antagonist and 5-HT_1A receptor agonist with a pIC₅₀ of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect .

HY-139748

ETX0462	Antibiotic Bacterial	Infection
S32212 is a serotonin type 2C receptor inverse agonist and an *α2 adrenoceptor* antagonist. S32212 exhibits antidepressant activity and can reduce immobility time in forced-swim test in rats .

HY-17034BR

Medetomidine hydrochloride (Standard) MPV785 (Standard)	Adrenergic Receptor Reference Standards	Neurological Disease Endocrinology
Medetomidine (hydrochloride) (Standard) is the analytical standard of Medetomidine (hydrochloride). This product is intended for research and analytical applications. Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-109075

Tasipimidine	Adrenergic Receptor	Neurological Disease
Tasipimidine is an orally active and selective *α_2A-adrenoceptor* agonist with a pEC₅₀ of 7.57 for human α_2A-adrenoceptors and an EC₅₀ of 5.7 nM for rat *α₂-adrenoceptor*. Tasipimidine can be utilized in research related to situational anxiety and fear .

HY-17034AS

Dexmedetomidine-13C,d3 hydrochloride (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease Endocrinology Cancer
Dexmedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-B0409AR

Clonidine hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Clonidine (hydrochloride) (Standard) is the analytical standard of Clonidine (hydrochloride). This product is intended for research and analytical applications. Clonidine hydrochloride is an agonist of α2-adrenoceptor and potent antihypertensive agent.

HY-B0374S

Moxonidine-d4	Isotope-Labeled Compounds Imidazoline Receptor Adrenergic Receptor LDLR	Cardiovascular Disease Neurological Disease
Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and *α₂ adrenoceptors*, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-A0008R

Talipexole dihydrochloride (Standard) B-HT 920 dihydrochloride (Standard)	Adrenergic Receptor Dopamine Receptor 5-HT Receptor Reference Standards	Neurological Disease Endocrinology
Talipexole (dihydrochloride) (Standard) is the analytical standard of Talipexole (dihydrochloride). This product is intended for research and analytical applications. Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.

HY-17034R

Medetomidine (Standard)	Adrenergic Receptor Reference Standards	Neurological Disease Endocrinology
Medetomidine (Standard) is the analytical standard of Medetomidine. This product is intended for research and analytical applications. Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-W263279

(E)-Guanabenz (E)-Wy-8678	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
(E)-Guanabenz ((E)-Wy-8678) is an orally active central *α2-adrenoceptor* agonist. (E)-Guanabenz has antihypertensive activity, acts via stimulating central α2-adrenoceptors, and reducing net sympathetic outflow into the periphery. (E)-Guanabenz also directly binds to and inhibits GADD34, and has neuroprotective activity. (E)-Guanabenz can be used for researching hypertension and Parkinson disease .

HY-W717221

Medetomidine-d5 (d5-Major)	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
Medetomidine-d₅ (d5-Major) is the deuterium labeled Medetomidine (HY-17034). Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-161836

α2AR agonist 1	Adrenergic Receptor	Cardiovascular Disease
α2AR agonist 1 (compound S6a), a new morpholine-containing pyrimidinone, acts as an agonist of *α2-adrenoceptor. α2AR agonist* 1 induces a concentration-dependent relaxation on aortic ring pre-contracted with Phenylephrine (HY-B0769; pEC₅₀=6.81). α2AR agonist 1 increases NOx and NO levels in HUVECs .

HY-12724AR

Guanabenz hydrochloride (Standard)	Parasite Adrenergic Receptor Reference Standards	Cardiovascular Disease Cancer
Guanabenz (hydrochloride) (Standard) is the analytical standard of Guanabenz (hydrochloride). This product is intended for research and analytical applications. Guanabenz hydrochloride is an orally active α-2-adrenoceptor agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure .

HY-106388A

Fadolmidine hydrochloride	Adrenergic Receptor	Neurological Disease
Fadolmidine hydrochloride is a novel, selective α2-adrenoceptor (α2-AR) agonist with EC₅₀ values of 0.4 nM, 4.9 nM and 0.5 nM for 2A, 2B and 2C, respectively. Fadolmidine hydrochloride has been effective against various submodalities of pain such as heat pain, mechanical pain, and visceral pain. Fadolmidine hydrochloride inhibits also electrically evoked contractions in rat vas deferens .

HY-123285

UK 14819 5-Desbromo, 5-chloro brimonidine	Adrenergic Receptor	Neurological Disease
UK 14819 (5-Desbromo, 5-chloro brimonidine) is an *α2-adrenoceptor* agonist. UK 14819 inhibits stimulation-induced contractions of rabbit distal colon with an IC₅₀ of 6.66 nM .

HY-B0194R

Tizanidine (Standard)	Reference Standards Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine (Standard) is the analytical standard of Tizanidine (HY-B0194). This product is intended for research and analytical applications. Tizanidine, a skeletal muscle relaxant, is an orally effective central *α₂-adrenoceptor* agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0194AR

Tizanidine hydrochloride (Standard)	Reference Standards Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine hydrochloride (Standard) is the analytical standard of Tizanidine hydrochloride (HY-B0194A). This product is intended for research and analytical applications. Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central *α₂-adrenoceptor* agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0194AS

Tizanidine-d4 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor Apoptosis Akt Wnt β-catenin	Neurological Disease Endocrinology Cancer
Tizanidine-d₄ hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central *α₂-adrenoceptor* agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-169791

ECPLA	5-HT Receptor	Neurological Disease
ECPLA, a lysergamide lysergic acid diethylamidean (LSD) analog, is a potent 5-HT2A agonist (EC₅₀ of 14.6 nM) for Gq-mediated calcium flux. ECPLA has high affinity for most serotonin receptors, α2-adrenoceptors, and D2-like dopamine receptors .

HY-12707C

Piribedil hydrochloride	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a *α2-adrenoceptors* antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707A

Piribedil dihydrochloride	Adrenergic Receptor Dopamine Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a *α2-adrenoceptors* antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707B

Piribedil maleate	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a *α2-adrenoceptors* antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707R

Piribedil (Standard)	Reference Standards Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a *α2-adrenoceptors* antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-106973A

Nolomirole hydrochloride CHF 1035	Dopamine Receptor Adrenergic Receptor	Cardiovascular Disease
Nolomirole (CHF 1035) hydrochloride is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output .

Cat. No.	Product Name	Chemical Structure

HY-17034BS1

Medetomidine-13C,d3 hydrochloride
Medetomidine-13C,d3 (hydrochloride) is a deuterated labeled Medetomidine (hydrochloride) . Medetomidine hydrochloride is an orally active *α2-adrenoceptor* agonist (K_i: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-B0194S

Tizanidine-d4

Tizanidine-d₄ is the deuterium labeled Tizanidine (HY-B0194). Tizanidine, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0409S

Clonidine-d4
Clonidine-d₄ is the deuterium labeled Clonidine. Clonidine hydrochloride is an agonist of α2-adrenoceptor and potent antihypertensive agent .

HY-17034AS

Dexmedetomidine-13C,d3 hydrochloride

Dexmedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .

HY-B0374S

Moxonidine-d4

Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-W717221

Medetomidine-d5 (d5-Major)
Medetomidine-d₅ (d5-Major) is the deuterium labeled Medetomidine (HY-17034). Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-B0194AS

Tizanidine-d4 hydrochloride

Tizanidine-d₄ hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-100490S

Rilmenidine-d4

Rilmenidine-d₄ is the deuterium labeled Rilmenidine. Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells .

HY-B0374S1

Moxonidine-d7

Moxonidine-d₇ is deuterated labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374AS

Moxonidine-13C,d3 hydrochloride

Moxonidine- ¹³C,d₃ hydrochloride is ¹³C and deuterated labeled Moxonidine hydrochloride (HY-B0374A). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374S2

Moxonidine-d3

Moxonidine-d₃ (BDF5895-d₃) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: